Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Biogen is a biotechnology company focused on neurological and neurodegenerative diseases, with core franchises in multiple sclerosis (Tecfidera, Tysabri, Vumerity) and spinal muscular atrophy (Spinraza). The company's competitive position has been challenged by biosimilar erosion in MS and the controversial Alzheimer's drug Aduhelm/Leqembi partnership with Eisai, while maintaining strong cash generation from legacy products. Stock performance is driven by pipeline progress in neuropsychiatry, Alzheimer's disease commercialization trajectory, and capital allocation decisions given the mature product portfolio.
Biogen generates revenue through proprietary biologic therapies for rare neurological conditions, leveraging high barriers to entry from complex manufacturing and specialized distribution networks. Pricing power derives from limited treatment alternatives in orphan indications, though facing pressure from payer scrutiny and biosimilar competition in mature MS markets. The company maintains 70%+ gross margins through high-value specialty products sold through controlled distribution channels, with significant operating leverage as R&D spending moderates from peak levels. Revenue sustainability depends on successfully transitioning from declining MS franchise to Alzheimer's disease opportunity and advancing mid-stage neuropsychiatry pipeline.
Leqembi commercial uptake metrics - quarterly patient starts, reimbursement coverage decisions, and market share versus competing amyloid therapies
MS franchise erosion rate - Tecfidera biosimilar penetration in Europe and US, Tysabri patient retention amid safety concerns
Pipeline readouts - Phase 2/3 data for neuropsychiatry assets (depression, schizophrenia programs), ALS candidates, and rare disease programs
Capital allocation announcements - share buyback authorizations, dividend policy, and M&A activity to supplement organic pipeline
Regulatory developments - FDA/EMA decisions on Alzheimer's disease diagnostic requirements, safety label updates for legacy products
Biosimilar competition accelerating across MS franchise - Tecfidera facing generic erosion, Tysabri patent expiration approaching, fundamentally resetting revenue base and requiring pipeline replacement
Alzheimer's disease market uncertainty - amyloid hypothesis validation still debated, CMS reimbursement restrictions limiting addressable market, competitive landscape intensifying with multiple anti-amyloid therapies approved
Regulatory scrutiny on accelerated approval pathway - FDA Aduhelm controversy creating heightened bar for neurological drug approvals, requiring larger confirmatory trials and longer development timelines
Pricing pressure from government negotiations - IRA drug price negotiation provisions targeting high-revenue products, potential Medicare Part D reforms affecting specialty drug reimbursement
MS market share loss to oral therapies and higher-efficacy biologics - Novartis Kesimpta, Roche Ocrevus capturing treatment-naive patients, eroding Biogen's first-line positioning
Gene therapy competition in SMA - Novartis Zolgensma one-time treatment challenging Spinraza's chronic dosing model, pricing dynamics favoring curative approaches despite upfront cost
Alzheimer's disease competitive intensity - Eli Lilly's donanemab showing potentially superior efficacy/safety profile versus Leqembi, Roche and other competitors advancing alternative mechanisms
Limited balance sheet risk given 0.38 debt/equity ratio and $2.1B annual free cash flow generation, providing substantial financial flexibility
Capital allocation execution risk - pressure to deploy cash through M&A to supplement pipeline may lead to value-destructive acquisitions at inflated biotech valuations, history of mixed M&A success
low - Biogen's neurological therapies address chronic, progressive diseases with limited treatment alternatives, creating relatively inelastic demand regardless of economic conditions. However, payer budget pressures and prior authorization requirements may tighten during recessions, potentially delaying treatment initiations. Commercial insurance mix (versus government payers) provides some GDP sensitivity, but overall revenue correlation to economic cycles is minimal given medical necessity of products.
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of long-duration pipeline assets, particularly impacting biotech valuations which rely heavily on out-year cash flows from development programs, and (2) increased financing costs for potential M&A activity, though Biogen's strong balance sheet (0.38 debt/equity) minimizes direct borrowing cost impact. The 2.68 current ratio and $2.1B free cash flow provide cushion against rate volatility. Rate increases also make dividend yields more competitive versus fixed income alternatives.
Minimal direct credit exposure as revenue derives from pharmaceutical distributors and specialty pharmacies with strong credit profiles, plus government payers (Medicare/Medicaid). Indirect exposure exists through hospital systems and payer financial health affecting reimbursement rates and formulary access, but diversified payer mix limits concentration risk. Strong investment-grade balance sheet eliminates refinancing concerns.
value - The stock trades at 2.9x price/sales and 10.5x EV/EBITDA, below historical biotech averages, attracting value investors focused on 7.1% FCF yield and potential pipeline optionality. Recent 42% six-month return suggests momentum investors entering on Alzheimer's disease optimism. Not a traditional growth stock given 1.4% revenue growth and mature product portfolio, but offers asymmetric upside if neuropsychiatry pipeline delivers. Dividend potential (strong FCF) may attract income-oriented healthcare investors seeking yield with biotech exposure.
high - Biotechnology stocks exhibit elevated volatility driven by binary clinical trial outcomes, regulatory decisions, and sentiment shifts on pipeline value. The 42% six-month return demonstrates momentum volatility. Estimated beta likely 1.2-1.4x given biotech sector characteristics, though lower than small-cap biotech due to established revenue base. Quarterly earnings volatility amplified by lumpy Spinraza dosing patterns and Alzheimer's franchise uncertainty.